8-K: Iterum Therapeutics Announces Positive Phase 3 Trial Results for Oral Sulopenem, Plans NDA Resubmission and Strategic Review

Iterum Therapeutics' oral sulopenem demonstrated statistical superiority over Augmentin in a Phase 3 trial for uncomplicated urinary tract infections, paving the way for a potential NDA resubmission and strategic review.

Summary

• Iterum Therapeutics announced positive topline results from its Phase 3 REASSURE clinical trial for oral sulopenem in treating uncomplicated urinary tract infections (uUTIs).
• The trial, conducted under a special protocol assessment (SPA) with the FDA, showed oral sulopenem was non-inferior to Augmentin, meeting the primary endpoint.
• Oral sulopenem demonstrated statistically significant superiority over Augmentin, with a 61.7% overall success rate compared to 55.0% for Augmentin.
• The safety profile of oral sulopenem was consistent with previous trials, with no new safety signals and fewer serious adverse events than Augmentin.
• The company plans to resubmit the New Drug Application (NDA) for oral sulopenem to the FDA in the second quarter of 2024.
• Iterum expects the FDA to complete its review and take action in the fourth quarter of 2024, six months after the NDA resubmission.
• The company is also initiating a strategic process to sell, license, or otherwise dispose of its rights to sulopenem to maximize value for stakeholders.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the successful trial results and the potential for NDA resubmission and strategic value creation. The company is moving forward with a clear plan, and the results are statistically significant.

Positives

• Oral sulopenem demonstrated statistically significant superiority over Augmentin in treating uUTIs.
• The safety profile of oral sulopenem was favorable, with no serious adverse events reported.
• The company is moving forward with the NDA resubmission, potentially leading to FDA approval.
• Iterum is actively pursuing strategic options to maximize the value of sulopenem.

Negatives

• The company received a Complete Response Letter (CRL) from the FDA in July 2021, which needs to be addressed in the resubmitted NDA.
• There is no guarantee that the strategic process to sell or license sulopenem will be successful.
• The company cannot provide any commitment regarding when or if the strategic process will result in any type of transaction.

Risks

• The resubmitted NDA must address all deficiencies identified in the FDA's Complete Response Letter from July 2021.
• The FDA review timeline is an estimate and could be subject to change.
• The strategic process to sell or license sulopenem may not result in a transaction.
• There are risks associated with the commercialization of sulopenem if approved, including competition and market acceptance.
• The company's ability to maintain its listing on the Nasdaq Capital Market is a risk factor.

Future Outlook

Iterum plans to resubmit the NDA for oral sulopenem in Q2 2024 and expects FDA action in Q4 2024, while also pursuing a strategic process to sell or license the rights to sulopenem.

Management Comments

• Corey Fishman, Iterum's CEO, stated they are very pleased with the positive data from the confirmatory trial.
• Corey Fishman mentioned the plan to resubmit the NDA in Q2 2024 and focus on a strategic process for sulopenem.
• Sailaja Puttagunta, Iterum's Chief Medical Officer, noted the results bring them closer to delivering a much-needed oral treatment option for women with uUTIs.

Industry Context

The announcement is significant as it addresses the growing need for new antibiotics to combat rising resistance, particularly in the uUTI market, which has seen limited innovation in recent years. The potential approval of oral sulopenem would provide a new treatment option in a market with over 30 million infections annually in the US.

Comparison to Industry Standards

• The trial compared oral sulopenem to Augmentin, a commonly used antibiotic for uUTIs, demonstrating superiority in overall response.
• The results are significant as they show a new oral antibiotic option that could address the increasing resistance to existing treatments.
• The safety profile of sulopenem was comparable to or better than Augmentin, which is a positive outcome.
• The company is aiming to be the first to market with an oral penem antibiotic in the US, which would be a significant achievement.

Stakeholder Impact

• Shareholders may benefit from the potential approval of sulopenem and the strategic process to maximize value.
• Patients with uUTIs could have a new treatment option if sulopenem is approved.
• Employees may be impacted by the strategic process, depending on the outcome.
• The company's suppliers and partners may be affected by the strategic decisions regarding sulopenem.

Next Steps

• Resubmit the New Drug Application (NDA) for oral sulopenem to the FDA in the second quarter of 2024.
• Focus on a strategic process to sell, license, or otherwise dispose of the rights to sulopenem.
• Present complete results from the REASSURE trial at an upcoming scientific meeting.

Key Dates

Keywords

sulopenem, urinary tract infections, uUTI, antibiotics, FDA, NDA, Phase 3 trial, Augmentin, strategic process, non-inferiority, superiority